Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14361MR)

This product GTTS-WQ14361MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14361MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2177MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ8895MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ12172MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ1134MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ9004MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ15285MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ8408MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ12127MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW